Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Next Previous
Drug Profile

Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Alternative Names: Anti-CD123 x Anti-CD3; Anti-CD19 X Anti-CD-3; Anti-CD86 X mono-IL-10; Anti-HER2 X Anti-CD3; Anti-RON X Anti-CD3; APVO-437; APVO210; APVO425; CD79BxDR; CD79BxDR Scorpion™ molecule; CTLA-4 X mono-IL-10; ES-425; ROR1 Bispecific; T-Scorp; TNFR x A2; TNFR x TWEAKR; X1 Anti-TNF-based SCORPION™; X1 TNF-based SCORPION™; X2 CTLA4-based SCORPION™

Latest Information Update: 28 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Aptevo Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Proteins; Small molecules
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors; CD3 antigen inhibitors; CD79 antigen inhibitors; CD86 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; ERBB 2 receptor antagonists; Glutamate carboxypeptidase II inhibitors; HLA-DR antigen inhibitors; Immunosuppressants; Receptor tyrosine kinase-like orphan receptor antagonists; RON protein inhibitors; TNFSF12 protein inhibitors; Tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Graft-versus-host disease; Irritable bowel syndrome; Rheumatoid arthritis

Most Recent Events

  • 28 Nov 2021 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA (Parenteral)
  • 28 Nov 2021 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA (Parenteral)
  • 28 May 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top